报价延迟最少15分钟:2025/10/24 07:02 EDT
盘前时段
|
||||
|
2.57 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.6803
|
|
|
| 价值评估 |
|
盈利(现时/预测)
33.63/-2.67
|
|
企业价值
5.31M
|
| 资产负债 |
|
每股账面净值
4.56
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
22.00K
|
|
每股收益
0.06
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/10/24 07:02 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EPprocedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension. |
